Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2021 08:05 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with...
October 12, 2021 08:35 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements

- Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR ...
April 13, 2021 08:05 ET | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval

- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...